IMS CORE lab teams up with Cristal Therapeutics
Cristal Therapeutics has announced that it has secured a Horizon 2020 grant. This allows the company to further develop the CriPec Nanomedicine Platform. This will be done in collaboration with the IMS CORE lab at Maastricht University’s M4I Division of Imaging Mass Spectrometry.
Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases. The ICARUS project will be carried out in close collaboration with the IMS CORE lab at the division of Imaging Mass Spectrometry, where CriPec® nanoparticle microlocalisation and drug release in tumours will be evaluated. Mass spectrometry imaging, technology together with Cristal Therapeutics’ expert team, will provide critical new insights to optimally design CriPec® nanomedicines with the aim of achieve superior therapeutic profiles.
The project at M4I will be led by Dr. Berta Cillero Pastor and by Prof. Ron Heeren.
For more details, read the full article on the Cristal Therapeutics website: http://cristaltherapeutics.com/cristal-therapeutics-awarded-horizon-2020-grant-to-further-develop-the-cripec-nanomedicine-platform/
Also read
-
Mimic the true nature of tissues by building complex in vitro models
Paul Wieringa (MERLN) works on innovative models to study endometriosis and the fallopian tube.
-
Vacancy: Farm-to-table Chef-designer-researcher
The Research, Education and Action Lab into Collective and Circular Transformation (REACCT) is looking for an experienced chef with a strong interest in research, farm-to-table experimental practices, and building design (two year part-time position).
-
BRAINS Consortium Awards Two New Research Projects
The BRAINS consortium has awarded two new research projects, bringing the total number to five.
